Trials / Completed
CompletedNCT00591136
Phase I Study of Indibulin in Patients With Solid Tumors
Dose-finding and Pharmacokinetic Trial of Orally Administered D-24851 to Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Dose-finding and pharmacokinetic trial of orally administered Indibulin to patients with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | indibulin | Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2008-01-11
- Last updated
- 2012-07-19
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00591136. Inclusion in this directory is not an endorsement.